Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
17:50:23 EDT Mon 30 Jun 2025
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

News for C:APLI from 2024-07-01 to 2025-06-30 - 41 items News ReleasesIn The NewsOther CAUS
DateSymCompanyPriceTypeHeadline
2025-06-25 20:49C:APLIAppili Therapeutics Inc0.015SEDAR Annual Information FormSEDAR Annual Information Form
2025-06-25 20:39C:APLIAppili Therapeutics Inc0.015SEDAR MD & ASEDAR MD & A
2025-06-25 20:26C:APLIAppili Therapeutics Inc0.015SEDAR Audited Annual Financial StatementsSEDAR Audited Annual Financial Statements
2025-06-25 18:04C:APLIAPPILI THERAPEUTICS INC. J0.015News ReleaseAppili Therapeutics Reports Fiscal Year 2025 Financial and Operational Results
2025-05-30 16:19C:APLIAppili Therapeutics Inc0.015News ReleaseAppili terminates arrangement with Aditxt
2025-05-20 02:24C:APLIAppili Therapeutics Inc0.03News ReleaseAppili to receive termination fee from Aditxt
2025-05-01 07:34C:APLIAPPILI THERAPEUTICS INC. J0.03News ReleaseAppili Therapeutics and Colleagues Publish Manuscript on the Prevention and Emergency Response to Tularemia
2025-04-28 17:47C:APLIAppili Therapeutics Inc0.03News ReleaseAppili Therapeutics granted patents in U.S., Mexico
2025-04-02 17:23C:APLIAppili Therapeutics Inc0.03News ReleaseAppili president to join Aditxt's April 4 update
2025-03-18 17:35C:APLIAppili Therapeutics Inc0.035News ReleaseAppili Therapeutics submits U.S. funding applications
2025-02-14 17:59C:APLIAppili Therapeutics Inc0.03SEDAR Interim MD & ASEDAR Interim MD & A
2025-02-14 17:53C:APLIAppili Therapeutics Inc0.03SEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2025-02-14 17:06C:APLIAPPILI THERAPEUTICS INC. J0.03News ReleaseAppili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2025
2024-12-12 08:15C:APLIAPPILI THERAPEUTICS INC. J0.035News ReleaseAditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic ADI Platform, Advancing Toward First-in-Human Clinical Trials
2024-11-19 16:31C:APLIAppili Therapeutics Inc0.03News ReleaseAppili receives final court order for Aditxt deal
2024-11-14 08:35C:APLIAppili Therapeutics Inc0.035SEDAR Interim MD & ASEDAR Interim MD & A
2024-11-14 08:29C:APLIAppili Therapeutics Inc0.035SEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2024-11-14 07:15C:APLIAPPILI THERAPEUTICS INC. J0.035News ReleaseAppili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025
2024-11-08 08:30C:APLIAPPILI THERAPEUTICS INC. J0.04News ReleaseAditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares
2024-11-07 08:30C:APLIAPPILI THERAPEUTICS INC. J0.035News ReleaseAditxt's Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders
2024-11-06 18:20C:APLIAppili Therapeutics Inc0.035News ReleaseAppili shareholders approve Aditxt deal
2024-11-06 08:30C:APLIAPPILI THERAPEUTICS INC. J0.04News ReleaseAditxt Acquisition Target Evofem Biosciences Secures Investor Support Through Voting Agreements for Merger with Aditxt's Subsidiary Adifem
2024-10-31 14:51C:APLIAppili Therapeutics Inc0.035News ReleaseAppili receives feedback from FDA for ATI-1801 plan
2024-10-31 08:30C:APLIAPPILI THERAPEUTICS INC. J0.035News ReleaseAditxt's Target Acquisition Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission
2024-10-30 17:35C:APLIAppili Therapeutics Inc0.035News ReleaseAppili Therapeutics to host conference call Nov. 1
2024-10-29 08:15C:APLIAPPILI THERAPEUTICS INC. J0.035News ReleaseSylvia Hermina Joins Aditxt's Board of Directors, Elevating Leadership with Broader Perspectives
2024-10-28 08:15C:APLIAPPILI THERAPEUTICS INC. J0.035News ReleaseAditxt Completes Final Equity Investment and Key Milestone Under the Amended and Restated Merger Agreement with Evofem
2024-10-17 07:15C:APLIAPPILI THERAPEUTICS INC. J0.035News ReleaseAppili Therapeutics Presents Update on ATI-1701 Biodefense Vaccine Candidate at IDWeek(TM) 2024
2024-10-10 16:07C:APLIAppili Therapeutics Inc0.025News ReleaseAppili acquiror Aditxt comments on acquisition
2024-10-10 16:02C:APLIAppili Therapeutics Inc0.025News ReleaseAppili corrects share acquisition price
2024-10-10 14:58C:APLIAppili Therapeutics Inc0.025News ReleaseAppili to hold special meeting Nov. 6 over Aditxt deal
2024-10-03 17:03C:APLIAppili Therapeutics Inc0.025News ReleaseAppili acquiror Aditxt needs $17M for acquisition
2024-09-17 17:36C:APLIAppili Therapeutics Inc0.03News ReleaseAppili shareholders approve AGM resolutions
2024-08-21 14:00C:APLIAppili Therapeutics Inc0.04News ReleaseAppili Therapeutics further extends Aditxt deal
2024-08-21 08:15C:APLIAPPILI THERAPEUTICS INC. J0.04News ReleaseAditxt Announces Third Amendment to Arrangement Agreement with Appili Therapeutics
2024-08-13 18:31C:APLIAppili Therapeutics Inc0.04SEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2024-08-13 18:31C:APLIAppili Therapeutics Inc0.04SEDAR Interim MD & ASEDAR Interim MD & A
2024-08-13 17:19C:APLIAPPILI THERAPEUTICS INC. J0.04News ReleaseAppili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2025
2024-07-25 08:30C:APLIAPPILI THERAPEUTICS INC. J0.03News ReleaseAditxt Signs Second Amendment to the Arrangement Agreement with Appili Therapeutics, Targeting September 30 Closing of the Acquisition
2024-07-18 17:56C:APLIAppili Therapeutics Inc0.035News ReleaseAppili Therapeutics amends agreement with Aditxt
2024-07-02 14:18C:APLIAppili Therapeutics Inc0.04News ReleaseAppili amends agreement with Aditxt, bridge loan